TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8881885

Group type: EXPERIMENTAL
Intervention: Low-energy extracorporal shock wave therapy (3000 impulses of 0.08 mJ/mm2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (30 impulses of 0.08 mJ/mm2)
Number of subjects: 50
Study: 8267195

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with patient‐controlled intravenous morphine (GA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural anesthesia combined with epidural fentanyl analgesia (RA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural anesthesia (RA)
Number of subjects: 60
Study: 3710294

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (60 mg daily)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 29985456

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27940686

Group type: EXPERIMENTAL
Intervention: Home-based early preventative care program with 9 home visits focusing on infant development, parental mental health, and parent-infant relationship.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Home-based early preventative care program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 25300221

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including implementation support, staff training, resources, recognition and incentives, consensus and leadership strategies, follow-up support and implementation feedback.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention support).
Number of subjects: 70
Study: 22068670

Group type: EXPERIMENTAL
Intervention: Polymethoxyethylacrylate (PMEA)‐coated circuits + leukocyte filters (n = 214)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Uncoated ECC + full Hammersmith aprotinin (n = 212)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: PMEA‐coated ECC + leukofilters + full Hammersmith aprotinin (n = 199)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Control - no treatment (n = 250)
Number of subjects: 875
Study: 20204892

Group type: EXPERIMENTAL
Intervention: Preceptor specialty (assigned randomly or by student recruitment/specialty request)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preceptor experience (time spent in ambulatory clinics and direct patient interaction)
Number of subjects: 0
Study: 17823507

Group type: EXPERIMENTAL
Intervention: Miswak extract rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 0
Study: 17564408

Group type: EXPERIMENTAL
Intervention: Sodium oxybate 9 g nightly
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sodium oxybate 6 g and 9 g nightly
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (all doses)
Number of subjects: 228
Study: 12244893

Group type: EXPERIMENTAL
Intervention: Enteroplant (enteric coated capsules containing 90 mg peppermint oil and 50 mg caraway oil each)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate release formulation (5 capsules containing 36 mg peppermint oil and 20 mg caraway oil each)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enteroplant (enteric coated capsules)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate release formulation
Number of subjects: 16
Study: 9889031

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 every 28 days for five cycles
Number of subjects: 81

Group type: COMPARATOR
Intervention: Epidoxorubicin 120 mg/m2 iv plus paclitaxel 150 mg/m2 iv every 28 days
Number of subjects: 81
Study: 7484887

Group type: EXPERIMENTAL
Intervention: Perindopril (4‐8 mg orally) with possible addition of isradipine (5‐10 mg orally) and hydralazine if necessary
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched normotensives)
Number of subjects: 25
Study: 1791799

Group type: EXPERIMENTAL
Intervention: Ambroxol (intravenous infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tokio‐Akita (TA) surfactant (endotracheal administration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (endotracheal administration)
Number of subjects: 30
Study: 532708

Group type: EXPERIMENTAL
Intervention: Thermography and plethysmography
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 55

Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 55
Study: 31756675

Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard neonatal care
Number of subjects: 19
Study: 31398441

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 mg caffeine (placebo)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TSD
Number of subjects: 12
Study: 28433216

Group type: EXPERIMENTAL
Intervention: MELD‐XI ≤16
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: MELD‐Na ≤17
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: MELD‐XI and MELD‐Na
Number of subjects: 453
Study: 26372318

Group type: EXPERIMENTAL
Intervention: Instruction in home heating
Number of subjects: 359
Study: 24064163

Group type: EXPERIMENTAL
Intervention: Bleached only (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acid-etched for 15 seconds prior to bleaching (Group 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acid-etched for 30 seconds prior to bleaching (Group 4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Group 1) - unbleached and had no previous acid etching
Number of subjects: 20
Study: 20678101

Group type: EXPERIMENTAL
Intervention: Laser welding with joint opening of 0·6 mm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser welding with joint opening of 0·0 mm and 3·5 mm diameter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Presence of porosity
Number of subjects: 60
Study: 18984662

Group type: COMPARATOR
Intervention: 240 mg/d oral iron alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 240 mg/d oral iron plus 75 microg/d levothyroxine
Number of subjects: 51
Study: 16893507

Group type: EXPERIMENTAL
Intervention: Insulin drip
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rotating fluids
Number of subjects: 36
Study: 15536773

Group type: EXPERIMENTAL
Intervention: Brief intervention with feedback on CDT levels
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 151
Study: 11419846

Group type: EXPERIMENTAL
Intervention: Screening group (flexible sigmoidoscopy)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 799
Study: 9285419

Group type: EXPERIMENTAL
Intervention: MRA (Magnetic Resonance Angiography)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MRI (Magnetic Resonance Imaging)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2-D TOF MRA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Spin-echo sequences
Number of subjects: 14

Group type: COMPARATOR
Intervention: Catheter angiography
Number of subjects: 14
Study: 8313865

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg bid)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500 mg tid)
Number of subjects: 497
Study: 3091629

Group type: EXPERIMENTAL
Intervention: GHRH pulses (1 microgram/kg, iv) at 2-h intervals during day (0900-2100 h) and night (2100-0900 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous GHRH infusion (0.15 microgram/kg X h for 5 h, followed by 0.75 microgram/kg X h for 5 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Single GHRH bolus dose (1 microgram/kg, iv) after continuous GHRH infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study: 31470942

Group type: EXPERIMENTAL
Intervention: Back-flow hydrodissection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional hydrodissection
Number of subjects: 200
Study: 29557398

Group type: EXPERIMENTAL
Intervention: Zygomatic implants
Number of subjects: 71

Group type: COMPARATOR
Intervention: Augmentation procedures
Number of subjects: 71
Study: 26463556

Group type: EXPERIMENTAL
Intervention: Ofloxacin drops
Number of subjects: 149

Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 149
Study: 25935963

Group type: EXPERIMENTAL
Intervention: 100 mg mifepristone
Number of subjects: 80

Group type: COMPARATOR
Intervention: 200 mg mifepristone
Number of subjects: 80
Study: 21891773

Group type: EXPERIMENTAL
Intervention: Extra high-volume hemofiltration (EHVHF) at 85 mL/kg/h
Number of subjects: 280

Group type: COMPARATOR
Intervention: High-volume hemofiltration (HVHF) at 50 mL/kg/h
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: EHVHF and HVHF
Number of subjects: 280
Study: 20358276

Group type: COMPARATOR
Intervention: Day 3 morphology score (Group A)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: GES-scoring plus sHLA-G expression (Group B)
Number of subjects: 214
Study: 17974605

Group type: EXPERIMENTAL
Intervention: Intra-arterial contrast injection (IACTA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional CT angiography with intravenous contrast injection (IVCTA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IACTA
Number of subjects: 32

Group type: COMPARATOR
Intervention: IVCTA
Number of subjects: 32
Study: 16026728

Group type: EXPERIMENTAL
Intervention: Original Focus on Kids (OFOK)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: West Virginia Focus on Kids (WVFOK)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Control condition (training in environmental conservation)
Number of subjects: 999
Study: 11859910

Group type: EXPERIMENTAL
Intervention: Almotriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 0
Study: 10612135

Group type: EXPERIMENTAL
Intervention: Arthroscopically assisted bone‐tendon‐bone A.C.L. reconstruction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open procedure A.C.L. reconstruction
Number of subjects: 64
Study: 8561671

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2024559

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 micrograms.ml‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 7044206

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31717739

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 28891388

Group type: EXPERIMENTAL
Intervention: High social-evaluative body image threat condition
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low social-evaluative body image threat condition
Number of subjects: 66
Study: 26581915

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 23754514

Group type: EXPERIMENTAL
Intervention: Darexaban-MR 120 mg qd + digoxin 0.25 mg qd
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + digoxin 0.25 mg qd
Number of subjects: 24
Study: 22960201

Group type: EXPERIMENTAL
Intervention: Spanish-English bilinguals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control native speakers of English
Number of subjects: 0
Study: 19574992

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg premedication
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both groups (Midazolam and Control)
Number of subjects: 179
Study: 17301626

Group type: EXPERIMENTAL
Intervention: Decision support tool training for GPs (4-hour interactive session)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Educational materials about guidelines (control group)
Number of subjects: 490
Study: 15965284

Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 12172464

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 10743479

Group type: EXPERIMENTAL
Intervention: 500 micrograms folic acid each day
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo tablet each day
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 500 micrograms folic acid and placebo tablets on alternate days
Number of subjects: 144
Study: 7723371

Group type: EXPERIMENTAL
Intervention: LPD (epirubicin 15-40 mg/m2 and Lipiodol 0.02-0.25 ml/kg)
Number of subjects: 43
Study: 2386364

Group type: COMPARATOR
Intervention: Intravenous cefetamet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral cefetamet pivoxil
Number of subjects: 24
Study: 7150459

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every 6 h for 4 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31221934

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 72
Study: 30594217

Group type: EXPERIMENTAL
Intervention: Disposable sanitary pads distribution
Number of subjects: 3489

Group type: EXPERIMENTAL
Intervention: Reproductive health education
Number of subjects: 3489

Group type: EXPERIMENTAL
Intervention: Sanitary pad distribution and reproductive health education
Number of subjects: 3489

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3489
Study: 27103467

Group type: EXPERIMENTAL
Intervention: Paracentesis and indwelling catheter drainage
Number of subjects: 78
Study: 24947926

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus vismodegib (VIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoothened (Smo) shRNA or vismodegib (VIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HH inhibition
Number of subjects: 0
Study: 22890878

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 1595

Group type: COMPARATOR
Intervention: Questionnaire by mail
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 1595
Study: 19717243

Group type: EXPERIMENTAL
Intervention: Behavioral Family Counseling (BFC) plus Individual-Based Treatment (IBT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT) alone
Number of subjects: 29
Study: 18779447

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (uncoated balloon)
Number of subjects: 87
Study: 16433710

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects (non-diabetic)
Number of subjects: 15
Study: 14633758

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 150

Group type: COMPARATOR
Intervention: 80% oxygen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 30% oxygen with droperidol 0.625 mg
Number of subjects: 150
Study: 10954389

Group type: EXPERIMENTAL
Intervention: Gatehouse Project intervention promoting healthy attachments, positive social climate, and curriculum-based health education.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curriculum-based health education integrated into mainstream curriculum.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linkage between school and broader community.
Number of subjects: 0
Study: 8682157

Group type: EXPERIMENTAL
Intervention: Standard 131I activity of 555 MBq
Number of subjects: 92

Group type: COMPARATOR
Intervention: Calculated activity to deliver a thyroid dose of 100 Gy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 92
Study: 1872664

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Methylcellulose
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Calcium polycarbophil
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 6763202

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg + Codeine 60 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg + Codeine 60 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 30526364

Group type: EXPERIMENTAL
Intervention: webCBT
Number of subjects: 594
Study: 28058962

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lidocaine (LI) injection
Number of subjects: 75
Study: 25599309

Group type: EXPERIMENTAL
Intervention: Individualized walking programme (WP)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Group exercise class (EC)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual physiotherapy (UP)
Number of subjects: 246
Study: 23475164

Group type: EXPERIMENTAL
Intervention: Nitrate-rich concentrated beetroot juice (BR; 2 × 250 mL·d, ∼8.2 mmol·d nitrate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitrate-depleted BR placebo (PL; 2 × 250 mL·d, ∼0.006 mmol·d nitrate)
Number of subjects: 9
Study: 21969639

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1460
Study: 19407730

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50-400 mg/day)
Number of subjects: 2950

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50 mg/day)
Number of subjects: 2950

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (400 mg/day)
Number of subjects: 2950

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2950

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 2950
Study: 17217572

Group type: EXPERIMENTAL
Intervention: 500 mg Ca/d
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1000 mg Ca/d
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0 mg Ca/d
Number of subjects: 21
Study: 15060225

Group type: EXPERIMENTAL
Intervention: Medication algorithm-medication alone (MedMgt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (Comb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavior modification (Beh)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community comparison (CC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Med/NoMed (stopping medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Med/Med (consistent medication use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NoMed/Med (starting medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NoMed/NoMed (never reported medication use)
Number of subjects: 0
Study: 11180733

Group type: EXPERIMENTAL
Intervention: Olympic Games transportation strategy
Number of subjects: 4
Study: 9676863

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg kg(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 7848364

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole preparations and placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multivitamin preparations and placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pain questionnaire
Number of subjects: 16
Study: 3261612

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (active treatment)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 59
Study: 30980569

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine practices in obstetrics
Number of subjects: 0
Study: 28686675

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg added after each IFNβ injection for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo added to the standard treatment for FLS for 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 24962864

Group type: EXPERIMENTAL
Intervention: LSG with omentopexy
Number of subjects: 60

Group type: COMPARATOR
Intervention: LSG without omentopexy (Control)
Number of subjects: 60
Study: 23701059

Group type: EXPERIMENTAL
Intervention: Intraparenchymal blood patch
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Intraparenchymal blood patch with 19-gauge needle
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Intraparenchymal blood patch with 17-gauge needle
Number of subjects: 242
Study: 21591944

Group type: EXPERIMENTAL
Intervention: Selenium (100 μg twice daily)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (600 mg twice daily)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 19246990

Group type: EXPERIMENTAL
Intervention: HCV Core ISCOMATRIX vaccine (5, 20, or 50 microg HCV Core protein with 120 mug ISCOMATRIX adjuvant)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 30
Study: 16918863

Group type: EXPERIMENTAL
Intervention: Nurse case management (CM) intervention
Number of subjects: 243

Group type: COMPARATOR
Intervention: Usual care (UC) condition
Number of subjects: 243
Study: 15157947

Group type: EXPERIMENTAL
Intervention: Fibromyalgia group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 0
Study: 11768700

Group type: EXPERIMENTAL
Intervention: Regular sugarless gum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bicarbonate sugarless gum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (normal postcibal buffering effects)
Number of subjects: 40